Bridge Medicines Hires Renzetti as Chief Scientific Officer

Louis Renzetti has been appointed chief scientific officer of New York-based Bridge Medicines. Renzetti most recently worked as chief research and early development officer of Gotham Therapeutics, another New York biotech startup. Before that, he was senior vice president of drug discovery and early development for Waltham, MA-based X-Rx. His experience also includes early drug discovery work at Roche. Bridge launched in 2016, aiming to develop drug candidates that come from academic institutions.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.